BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A. Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. Eur J Nucl Med Mol Imaging 2018;45:1233-41. [PMID: 29470615 DOI: 10.1007/s00259-018-3964-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Fanti S, Bonfiglioli R, Decristoforo C. Highlights of the 30th Annual Congress of the EANM, Vienna 2017: "Yes we can - make nuclear medicine great again". Eur J Nucl Med Mol Imaging 2018;45:1781-94. [PMID: 29725717 DOI: 10.1007/s00259-018-4029-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
2 Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv 2020;4:4091-101. [PMID: 32877524 DOI: 10.1182/bloodadvances.2020002583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Løndalen A, Blakkisrud J, Revheim ME, Dahle J, Kolstad A, Stokke C. FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target? Mol Imaging Biol 2022. [PMID: 35486292 DOI: 10.1007/s11307-022-01731-3] [Reference Citation Analysis]
4 Blakkisrud J, Løndalen A, Dahle J, Martinsen AC, Kolstad A, Stokke C. Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable. Acta Oncol 2021;60:1481-8. [PMID: 34425735 DOI: 10.1080/0284186X.2021.1959635] [Reference Citation Analysis]
5 Sabanathan D, Lund ME, Campbell DH, Walsh BJ, Gurney H. Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target. Ther Adv Med Oncol 2021;13:17588359211022918. [PMID: 34646364 DOI: 10.1177/17588359211022918] [Reference Citation Analysis]
6 Lakes AL, An DD, Gauny SS, Ansoborlo C, Liang BH, Rees JA, McKnight KD, Karsunky H, Abergel RJ. Evaluating 225Ac and 177Lu Radioimmunoconjugates against Antibody-Drug Conjugates for Small-Cell Lung Cancer. Mol Pharm 2020;17:4270-9. [PMID: 33044830 DOI: 10.1021/acs.molpharmaceut.0c00703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Marques MRC, Choo Q, Ashtikar M, Rocha TC, Bremer-Hoffmann S, Wacker MG. Nanomedicines - Tiny particles and big challenges. Adv Drug Deliv Rev 2019;151-152:23-43. [PMID: 31226397 DOI: 10.1016/j.addr.2019.06.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 15.0] [Reference Citation Analysis]